RecruitingNCT03910569

The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study

Smidt Heart Institute Takotsubo Registry


Sponsor

Cedars-Sinai Medical Center

Enrollment

1,000 participants

Start Date

Feb 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Have received a diagnosis of Takotsubo from their physician and consent to enroll
  • Submit full medical records needed for Takotsubo adjudication

Exclusion Criteria3

  • Younger than 18 years
  • Unable to provide informed consent
  • Unable to provide the necessary documentation needed for screening purposes

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Cedars Sinai Medical Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03910569


Related Trials